Glioma-associated oncogene homolog 1 (GLI1)

Glioma-associated oncogene homolog 1 (GLI1) is a Krüppel-like zinc finger transcription factor that serves as the primary terminal effector of the Hedgehog (Hh) signaling pathway (Wikipedia; GeneCards). Originally identified as an amplified gene in human glioblastoma, it plays a critical role during embryonic development in processes such as tissue patterning, organogenesis, and cell fate determination (Kinzler et al., 1987; UniProt). In adult organisms, GLI1 expression is typically low, though it remains important for regulating various stem cell populations and maintaining tissue homeostasis (Avery et al., 2021). Pathological overactivation of GLI1 is a hallmark of many aggressive cancers, driven either by canonical Hh signaling or through non-canonical crosstalk with pathways such as RAS/MAPK and PI3K/AKT (Rimkus et al., 2016; Avery et al., 2021). In these oncogenic contexts, GLI1 facilitates the transcription of genes that promote cell cycle progression, survival, metastasis, and resistance to standard chemotherapies (Zolota et al., 2021). As a therapeutic target, GLI1 is vital for treating tumors that exhibit resistance to upstream Smoothened (SMO) inhibitors (Dusek & Hadden, 2021; Zolota et al., 2021). Current pharmacological strategies involve small molecules that directly inhibit GLI1-DNA binding or promote protein degradation to treat Hedgehog-dependent malignancies like basal cell carcinoma and medulloblastoma (Hadden Lab; Zolota et al., 2021).

Other names

Zinc finger protein GLI1Glioma-associated oncogene 1GLI family zinc finger 1GLI1GLIPAPA8PPD1

Drugs targeting GLI1 typically act through direct inhibition of its transcriptional activity by disrupting DNA sequence recognition, promoting its proteasomal degradation (e.g., arsenic trioxide), or inhibiting its nuclear translocation from the cytoplasm (Zolota et al., 2021; Hadden Lab).